Aytu Biopharma Inc (AYTU) Stock Price, Quote & News

Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 720 437 6580

Website: aytubio.com

Address:

Denver Corporate Center III, Suite 920 7900 East Union Avenue, Denver, United States

Dolphinsarecute Feb. 18 at 7:28 PM

$AYTU Remember that there's a tomorrow tomorrow as well! Moonshot! Give this guy a follow if you've got too much money sitting around!

1 · Reply

HiPlainsTrader Feb. 18 at 1:54 PM

$AYTU where’s my light!?

0 · Reply

PortfolioQuintessence Feb. 17 at 1:15 PM

$AYTU Pre-revenue biotech; early-stage.

1 · Reply

TradeNiko Feb. 17 at 8:50 AM

$AYTU Pre-revenue biotech; early-stage

0 · Reply

BillionerOfKing Feb. 13 at 2:54 AM

$AYTU Current Stock Price: $2.18

0 · Reply

CodeCatalyst Feb. 9 at 3:14 PM

$AYTU Biotech with diversified therapeutic focus; resources are spread thin.

0 · Reply

Fffrre321 Feb. 6 at 3:13 PM

$AYTU Trumprx is on. Exua meets Trump's requirements. 1. Manufacturing plants in the U.S. 2. Cheap prices 3. Self-platforms 4. First depressive drug with less side effects AYTU must actively participate in TrumpRX to increase the number of prescriptions and have a marketing opportunity to promote new drugs to patients. Signing with the government with news of the release of new drugs could have huge long-term benefits. This is a huge social issue in the U.S. aaytu is a fool if you miss this opportunity

1 · Reply

Dolphinsarecute Feb. 4 at 8:45 PM

$AYTU I recommend you go all in. Can't get a more serious company, CEO OR stock! Buy all you can, this is going to at least 20, yesterday AH!!!!!

1 · Reply

Henry20feb_ Feb. 4 at 3:06 PM

$AYTU This is more “steady specialty pharma with an upside catalyst” than “binary biotech moonshot.” If EXXUA ramps, EBITDA likely flips positive fast. If not, downside seems cushioned by the existing $15M/quarter base. Next 2–3 quarters = all about EXXUA scripts, not GAAP net loss noise!

1 · Reply

kareem1988 Feb. 4 at 10:11 AM

Yesterday, while the broader market felt the heat, a few high-conviction names managed to push through the noise with strong technical moves. Leading the pack was $DRTS , which surged nearly +5% on heavy accumulation. $DRTS (+4.9%) The standout performer. While most tech/bio names stayed flat, $DRTS moved on high volume as investors front-run the pending Japan PMDA decision. The technical "buy the dip" trend we saw last week is officially turning into a breakout. $VNDA (+4.0%): Gaining momentum as the market starts pricing in a positive Feb 21 FDA decision for Bysanti. $AYTU (+4.2%): Rallied after beating Q2 revenue estimates and confirming a strong launch for EXXUA. $AXSM (+0.8% / +4% Intraday): Reached $190+ before settling. Still holding near 52-week highs as blockbuster sales for Auvelity continue. Clinical wins > Macro noise. 📈

1 · Reply

Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript

Feb 3, 2026, 4:05 PM EST - 17 days ago

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Jan 27, 2026, 4:05 PM EST - 24 days ago

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Jan 20, 2026, 8:05 PM EST - 4 weeks ago

Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript

Jan 20, 2026, 4:05 PM EST - 4 weeks ago

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Jan 13, 2026, 4:15 PM EST - 5 weeks ago

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Jan 12, 2026, 8:00 AM EST - 5 weeks ago

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Dec 18, 2025, 9:00 AM EST - 2 months ago

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

Dec 15, 2025, 9:00 AM EST - 2 months ago

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Nov 24, 2025, 4:05 PM EST - 3 months ago

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 13, 2025, 9:21 PM EST - 3 months ago

Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 3 months ago

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 5, 2025, 4:05 PM EST - 3 months ago

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Oct 28, 2025, 9:00 AM EDT - 4 months ago

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 10, 2025, 9:00 AM EDT - 4 months ago

Aytu BioPharma to Present at Upcoming October 2025 Conferences

Sep 24, 2025, 4:15 PM EDT - 5 months ago

Aytu BioPharma to Present at Upcoming September 2025 Conferences

Sep 23, 2025, 9:43 PM EDT - 5 months ago

Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript

Sep 23, 2025, 4:05 PM EDT - 5 months ago

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 16, 2025, 4:05 PM EDT - 5 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

Jun 25, 2025, 8:00 AM EDT - 8 months ago

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

Jun 23, 2025, 8:00 AM EDT - 8 months ago

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 9, 2025, 4:30 PM EDT - 9 months ago

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

Jun 6, 2025, 8:01 AM EDT - 9 months ago

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025, 8:00 AM EDT - 9 months ago

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

May 14, 2025, 8:29 PM EDT - 10 months ago

Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 10 months ago

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 7, 2025, 4:15 PM EDT - 10 months ago

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Apr 21, 2025, 4:05 PM EDT - 10 months ago

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Feb 12, 2025, 6:27 PM EST - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript

Feb 12, 2025, 4:03 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 5, 2025, 5:50 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Jan 6, 2025, 9:00 AM EST - 1 year ago

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 3, 2024, 11:45 PM EST - 1 year ago

Aytu BioPharma Disclosure Notification

Nov 22, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 13, 2024, 7:25 PM EST - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 6, 2024, 5:20 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Oct 14, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Sep 26, 2024, 6:51 PM EDT - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript

Sep 26, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 19, 2024, 5:30 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aug 8, 2024, 5:20 PM EDT - 1 year ago

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

May 15, 2024, 8:28 PM EDT - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

May 8, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Feb 14, 2024, 10:52 PM EST - 2 years ago

Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript

Dolphinsarecute Feb. 18 at 7:28 PM

$AYTU Remember that there's a tomorrow tomorrow as well! Moonshot! Give this guy a follow if you've got too much money sitting around!

1 · Reply

HiPlainsTrader Feb. 18 at 1:54 PM

$AYTU where’s my light!?

0 · Reply

PortfolioQuintessence Feb. 17 at 1:15 PM

$AYTU Pre-revenue biotech; early-stage.

1 · Reply

TradeNiko Feb. 17 at 8:50 AM

$AYTU Pre-revenue biotech; early-stage

0 · Reply

BillionerOfKing Feb. 13 at 2:54 AM

$AYTU Current Stock Price: $2.18

0 · Reply

CodeCatalyst Feb. 9 at 3:14 PM

$AYTU Biotech with diversified therapeutic focus; resources are spread thin.

0 · Reply

Fffrre321 Feb. 6 at 3:13 PM

1 · Reply

Dolphinsarecute Feb. 4 at 8:45 PM

$AYTU I recommend you go all in. Can't get a more serious company, CEO OR stock! Buy all you can, this is going to at least 20, yesterday AH!!!!!

1 · Reply

Henry20feb_ Feb. 4 at 3:06 PM

1 · Reply

kareem1988 Feb. 4 at 10:11 AM

1 · Reply

YourObscureCEOforLife Feb. 3 at 11:46 PM

$AYTU so how's that moonshot working out for you?

0 · Reply

Comet127 Feb. 3 at 10:24 PM

$AYTU Correction to my last post. According to ChatGPT, Jared Disbrow made $549,247 total compensation in 2025. Not over $580K. I feel he should receive more money and so should Josh Disbrow. My prediction is this stock is going over 80$ a share in the near future. Cash in your 401k and put all of it in AYTU. Buy as much as you can.

2 · Reply

Henry20feb_ Feb. 3 at 10:08 PM

$AYTU Q2 FY26 in one take: This is a disciplined, low-burn launch, not a cash-hungry biotech gamble — ~$15M quarterly revenue, ~63% margins, near-breakeven EBITDA, and ~$30M cash with minimal burn. The risk isn’t dilution, it’s whether EXXUA ramps fast enough to re-accelerate growth over the next few quarters.

0 · Reply

Comet127 Feb. 3 at 9:52 PM

$AYTU Way to earn that annual salary of over $920K Josh Disbrow. Your brother Jared makes over $586K. You both definitely deserve that money from selling shares of stock and never hurting anybody or taking advantage of them. In fact, I think you should celebrate this earnings report by taking the AYTU board of directors out for a big fat steak dinner with expensive wines at a Ritz Carlton. Maybe use the company American Express corporate card so it doesn’t affect your finances. Congratulations on a job well done over the last 6 years. You are a positive influence in the world who is spiritual and must sleep very well at night. Not like other CEO’s who end up on American Greed episodes for ruining lives, famalies, dreams and marriages.

0 · Reply

Telorino Feb. 3 at 9:23 PM

$AYTU So this Q the company lost money because the stock price went up… Is that? Did I read that right?

3 · Reply

Alain_Simard Feb. 3 at 9:22 PM

$AYTU 💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩💩

0 · Reply

GoWhiteSox Feb. 3 at 9:18 PM

$AYTU https://feeds.issuerdirect.com/news-release.html?newsid=7089077386821056&symbol=AYTU

0 · Reply

perasomillionaire Feb. 2 at 4:02 PM

@BioRich @BioRich whats your opinion on $AYTU I believe tomorrow will move hard

1 · Reply

perasomillionaire Feb. 2 at 10:57 AM

$AYTU it’s odd being here with almost 0 interaction for a stock that is about to run over 1000% in a single day… less than 36 hours for this to moonshot

1 · Reply

perasomillionaire Feb. 2 at 10:54 AM

$AYTU

0 · Reply

perasomillionaire Feb. 2 at 10:54 AM

$AYTU In an ultra-conservative scenario where only 1% of the ~15 million U.S. patients who suffer antidepressant-related sexual side effects adopt EXXUA, that implies ~150,000 patients. At an estimated net revenue of roughly $10,700 per patient per year (after typical gross-to-net discounts), this translates into approximately $1.6 billion in annual net sales. Applying very conservative pharmaceutical multiples of 2× sales implies an equity value of around $3 billion. Given that Aytu’s current sub-$30 million market cap effectively prices in a near-failure or pre-bankruptcy outcome, a re-rating to a ~$3 billion market cap is not an aggressive assumption but a realistic one contingent solely on minimal, demonstrable commercial adoption rather than market dominance.

1 · Reply

perasomillionaire Jan. 30 at 10:44 PM

$AYTU only need to say: “EXXUA launch is a success.” and boom 1000% Current market cap predicts collapse of the entire company. Worst of all is already priced in. Nobody is watching this stock. Nobody cares. Everybody will join at levels where I will be selling.

1 · Reply

Market Cap	24.79M
Revenue (ttm)	66.38M
Net Income (ttm)	-13.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.43%
Debt to Equity Ratio	1.47

Volume	14,400
Avg Vol	106,958
Day's Range	N/A - N/A
Shares Out	10.73M
Stochastic %K	59%
Beta	0.37
Analysts	Sell
Price Target	$9.33